Patents by Inventor Albert H. Meier
Albert H. Meier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5716933Abstract: A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertabrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity.Type: GrantFiled: May 26, 1995Date of Patent: February 10, 1998Assignee: Louisiana State University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5716957Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 5, 1995Date of Patent: February 10, 1998Assignees: The Board of Supervisors of Louisiana State and Agricultural and Mechanical College, Ergo Research CorporationInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5716962Abstract: A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.Type: GrantFiled: June 6, 1995Date of Patent: February 10, 1998Assignee: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5716932Abstract: A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity.Type: GrantFiled: May 26, 1995Date of Patent: February 10, 1998Assignee: Louisiana State University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5714519Abstract: This invention relates to a method for modifying metabolism in a vertebrate animal which entails the administration of pantethine or cysteamine at a predetermined time daily. The method is useful in the treatment of hyperglycemia, glucose intolerance, insulin resistance, and hyperinsulinemia.Type: GrantFiled: June 7, 1995Date of Patent: February 3, 1998Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5712265Abstract: Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.Type: GrantFiled: June 1, 1995Date of Patent: January 27, 1998Assignees: The General Hospital Corporation, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5700795Abstract: Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.Type: GrantFiled: June 1, 1995Date of Patent: December 23, 1997Assignees: The General Hospital Corporation, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5700800Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: October 31, 1995Date of Patent: December 23, 1997Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5696128Abstract: Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.Type: GrantFiled: July 7, 1994Date of Patent: December 9, 1997Assignees: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College, The General Hospital CorporationInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5688794Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of non-insulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, or a prolactin stimulating compound.Type: GrantFiled: October 31, 1995Date of Patent: November 18, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5668155Abstract: Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.Type: GrantFiled: June 20, 1994Date of Patent: September 16, 1997Assignees: The General Hospital Corporation, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5665375Abstract: A method for reducing the total fat and cholesterol contents and the ratio of saturated to unsaturated fatty acids and for increasing total protein content in eggs produced by animals is described. The level of n-Dihydroxyphenylalanine (L-DOPA) in the bloodstream of the poultry is elevated so as to cause the animals to produce eggs which have a reduced cholesterol content and eggs which have a lower ratio of saturated to unsaturated fatty acids. In a preferred embodiment the L-DOPA is orally administered to poultry by incorporation in the food for said poultry.Type: GrantFiled: May 31, 1995Date of Patent: September 9, 1997Assignee: Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, John M. Wilson
-
Patent number: 5654313Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5650438Abstract: A process is provided for activating reproduction in seasonal breeding vertebrates during normally non-reproductive seasons by administering L-dihydroxyphenylalanine (L-DOPA), thereby increasing the level of L-DOPA in the vertebrate's bloodstream to a reproductively active level. An effective amount of 5-HTP can also be injected into the vertebrate followed, an effective period of time later, with an injection of an effective amount of L-DOPA.Type: GrantFiled: June 5, 1995Date of Patent: July 22, 1997Assignee: The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, John M. Wilson
-
Patent number: 5635512Abstract: A process for the long term modification and regulation of linid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 5, 1995Date of Patent: June 3, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana Business and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5626860Abstract: Disclosed herein are methods for regulating or ameliorating lipid and glucose metabolism and reducing in a vertebrate animal body fat stores, insulin resistance, hyperinsulinemia, hyperglycemia, hyperlipidemia, elevated blood lipoproteins (such as triglycerides and cholesterol including chylomicrons, VLDL and LDL) and/or increasing in the subject the plasma HDL. The methods comprise administration or timed administration of inhibitors of dopamine beta hydroxylase (DBH).Type: GrantFiled: June 7, 1995Date of Patent: May 6, 1997Assignees: The Board of Supervisors of Louisana State and Agricultural and Mechanical College, Ergo Science IncorporatedInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5585347Abstract: Disclosed are methods for detecting abnormalities in prolactin daily rhythms. The methods involve comparing a prolactin profile of a vertebrate (including a human) subject being tested that has been compiled over a predetermined period to a predetermined standard prolactin profile for healthy subjects. The method also involves determining whether the vertebrate subject has an abnormal daily prolactin rhythm by ascertaining whether (i) at any point during waking hours the prolactin level of the subject being tested is greater than 1 SEM above the normal prolactin profile of said healthy subjects, and/or (ii) at any point during sleeptime the prolactin level of the subject being tested is at least 1 SEM lower than the normal prolactin profile of said healthy subjects. Also provided are methods for determining adjustments needed to an abnormal prolactin profile (or daily rhythm) to cause it to conform to the prolactin profile (or rhythm) of a healthy subject, and methods for effecting such adjustments.Type: GrantFiled: December 22, 1992Date of Patent: December 17, 1996Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana State Univerisity and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5554623Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: May 26, 1994Date of Patent: September 10, 1996Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5496803Abstract: A process for the long-term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long-term basis by treatment corresponding to that of the treatment for obesity.Type: GrantFiled: August 8, 1994Date of Patent: March 5, 1996Assignee: Louisiana State University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5468755Abstract: A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.Type: GrantFiled: November 24, 1993Date of Patent: November 21, 1995Assignee: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier